Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 1.00 |
| ▸ | GRM7 | Q14831 | 4/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173391 | 0.76 | IDO1 (0.61) | IDO1GRM7MTNR1AMTNR1BMAPT | |
| SCHEMBL3428492 | 0.75 | IDO1 (0.59) | IDO1GRM7MTNR1AMTNR1BMAPT | |
| SCHEMBL31141646 | 0.72 | IDO1 (0.56) | IDO1GRM7MTNR1AMTNR1BMAPT | |
| SCHEMBL6153717 | 0.72 | IDO1 (0.56) | IDO1GRM7MTNR1AMTNR1BMAPT | |
| SCHEMBL173810 | 0.71 | IDO1 (0.56) | IDO1GRM7MTNR1AMTNR1BMAPT | |
| SCHEMBL30595323 | 0.71 | MTNR1A (0.77) | IDO1GRM7MTNR1AMTNR1BMAPT | |
| SCHEMBL1029693 | 0.71 | MTNR1A (0.77) | IDO1GRM7MTNR1AMTNR1BMAPT | |
| SCHEMBL19101077 | 0.71 | IDO1 (0.53) | IDO1MAPTNPC1LMNARAB9A | |
| SCHEMBL6950748 | 0.71 | — | — | |
| SCHEMBL9851524 | 0.68 | GRM7 (0.59) | IDO1GRM7MTNR1AMTNR1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940787-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INST MEDICAL RES (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1940787-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | Lankenau Institute for Medical Research (US) | 2008-07-09 | — | — | EP | claimed |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-10 | — | — | US | claimed |
| WO-2007050963-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-05-03 | — | — | WO | claimed |
| US-20120142750-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2012-06-07 | — | — | US | disclosed |
| US-20120142750-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2012-06-07 | — | — | US | disclosed |
| US-20100166881-A1 | Novel IDO Inhibitors and Methods of Use Thereof | PRENDERGAST GEORGE C | 2010-07-01 | — | — | US | disclosed |
| US-7705022-B2 | N-[2-(Indol-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(benzo[b]thiophen-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(indol-3-yl)ethyl]-S[(naphth-2-yl)methyl]-dithiocarbamate; anticarcinogenic agents; free of brassinin | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1940787-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INST MEDICAL RES (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090155311-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | MED. COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155311-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | MED. COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1940787-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | Lankenau Institute for Medical Research (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007081878-A2 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-10 | — | — | US | disclosed |
| WO-2007050963-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155311-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | IDO2, IDO1, INMT | IDO1 2/4885GRM7 2537/4885MTNR1A 47/4885 |
| US-20100166881-A1 | Novel IDO Inhibitors and Methods of Use Thereof | IDO1, IDO2, INMT | IDO1 1/4885GRM7 1854/4885MTNR1A 278/4885 |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | IDO1, IDO2, INMT | IDO1 1/4885GRM7 1854/4885MTNR1A 278/4885 |
| US-20120142750-A1 | INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS | IDO2, IDO1, INMT | IDO1 2/4885GRM7 2537/4885MTNR1A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.